Objective: To study the effect of immunotherapy combined with intravenous chemotherapy on the tumor load, immune function and cancer cell proliferation activity in patients with advanced colon cancer. Methods: A total...Objective: To study the effect of immunotherapy combined with intravenous chemotherapy on the tumor load, immune function and cancer cell proliferation activity in patients with advanced colon cancer. Methods: A total of 90 patients with advanced colon cancer who were treated in Second People's Hospital of Yibin between December 2014 and January 2017 were collected and divided into control group (n=45) and observation group (n=45) by random number table. Control group received routine intravenous chemotherapy, and the observation group received immunotherapy combined with intravenous chemotherapy. The levels of specific tumor markers and Th17/Treg cytokines in serum as well as proliferation gene expression in the lesion tissue were determined. Results: Before treatment, the differences in levels of specific tumor markers and Th17/Treg cytokines in serum as well as proliferation gene expression in lesion tissue were not statistically significant between the two groups. After treatment, PTN, CCSA-1, IL-17 and IL-23 levels in serum as well as GTPBP4 and PIK3CB mRNA expression in lesion tissue of both groups of patients were lower than those before treatment while IL-10 and IL-35 levels in serum as well as FAM96B, MS4A12 and FRAT1 mRNA expression in lesion tissue were higher than those before treatment, and PTN, CCSA-1, IL-17 and IL-23 levels in serum as well as GTPBP4 and PIK3CB mRNA expression in lesion tissue of observation group were lower than those of control group while IL-10 and IL-35 levels in serum as well as FAM96B, MS4A12 and FRAT1 mRNA expression in lesion tissue were higher than those of control group. Conclusion: Immunotherapy combined with intravenous chemotherapy can effectively reduce the tumor load, optimize cellular immune function and inhibit tumor cell proliferation in patients with advanced colon cancer.展开更多
文摘Objective: To study the effect of immunotherapy combined with intravenous chemotherapy on the tumor load, immune function and cancer cell proliferation activity in patients with advanced colon cancer. Methods: A total of 90 patients with advanced colon cancer who were treated in Second People's Hospital of Yibin between December 2014 and January 2017 were collected and divided into control group (n=45) and observation group (n=45) by random number table. Control group received routine intravenous chemotherapy, and the observation group received immunotherapy combined with intravenous chemotherapy. The levels of specific tumor markers and Th17/Treg cytokines in serum as well as proliferation gene expression in the lesion tissue were determined. Results: Before treatment, the differences in levels of specific tumor markers and Th17/Treg cytokines in serum as well as proliferation gene expression in lesion tissue were not statistically significant between the two groups. After treatment, PTN, CCSA-1, IL-17 and IL-23 levels in serum as well as GTPBP4 and PIK3CB mRNA expression in lesion tissue of both groups of patients were lower than those before treatment while IL-10 and IL-35 levels in serum as well as FAM96B, MS4A12 and FRAT1 mRNA expression in lesion tissue were higher than those before treatment, and PTN, CCSA-1, IL-17 and IL-23 levels in serum as well as GTPBP4 and PIK3CB mRNA expression in lesion tissue of observation group were lower than those of control group while IL-10 and IL-35 levels in serum as well as FAM96B, MS4A12 and FRAT1 mRNA expression in lesion tissue were higher than those of control group. Conclusion: Immunotherapy combined with intravenous chemotherapy can effectively reduce the tumor load, optimize cellular immune function and inhibit tumor cell proliferation in patients with advanced colon cancer.
